Ameriprise’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Ameriprise’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-116,228	Closed	-$11.3M	–	4148
2015 Q1	$11.3M	Sell	116,228 -25,545	-18%	-$2.7M	0.01%	1456
2014 Q4	$13.2M	Buy	141,773 +180	+0.1%	+$14.2K	0.01%	1280
2014 Q3	$9.74M	Sell	141,593 -19,420	-12%	-$1.39M	0.01%	1493
2014 Q2	$16.9M	Buy	161,013 +29,229	+22%	+$2.49M	0.01%	1149
2014 Q1	$10.9M	Buy	131,784 +3,744	+3%	+$346K	0.01%	1432
2013 Q4	$8.29M	Sell	128,040 -8,025	-6%	-$476K	0.01%	1639
2013 Q3	$8.61M	Buy	136,065 +21,438	+19%	+$1.06M	0.01%	1568
2013 Q2	$4.82M	Buy	+114,627	New	+$5.22M	﹤0.01%	1904

Ameriprise's GEVA Position: Q2 2015 in Review

Ameriprise sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 116,228 shares — an estimated $11.3M sold.

Ameriprise first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $16.9M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Ameriprise reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Ameriprise sold 116,228 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $11.3M.
Ameriprise first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Ameriprise's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $16.9M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Ameriprise's 13F filing for Q2 2015, filed 13 Aug 2015.